GGrantIndex
← Leaderboards

James Steven Leeder

Children'S Mercy Hosp (Kansas City, Mo)

Google Scholar ↗PubMed ↗ORCID ↗
$15,267,008
Attributed
$25,890,567
Total exposure
13
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.2M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$29,363,916 · 15

By mechanism

UL1$15,160,993 · 1
R01$4,099,566 · 2
U54$3,936,667 · 3
P50$2,374,013 · 3
OT2$1,500,000 · 1
U01$1,484,792 · 1

Top collaborators

Most similar at Children'S Mercy Hosp (Kansas City, Mo)

Same institution · by research overlap

Others in their field

Top investigators on “Child”

Research focus

ChildChildhoodPharmacogeneticsDoseGrowthPharmaceutical PreparationsGenomicsPediatric PharmacologyResponseLinkHospitalsBaseClinical ResearchPharmacogenomicsProgramsCollaborationsInnovationMetabolismKansasPediatricsHealthcareResearch PersonnelClinical PharmacologyInterest

Grant awards (46)

Frontiers Clinical and Translational Science Institute at the University of Kansas$3,708,319
UL1 · FY2025 · TR
All of Us Research Program Heartland Consortium (AoURP-HC)$1,500,000
OT2 · FY2025 · OD
Frontiers Clinical and Translational Science Institute at the University of Kansas$3,817,944
UL1 · FY2024 · TR
Frontiers Clinical and Translational Science Institute at the University of Kansas$3,817,944
UL1 · FY2023 · TR
Frontiers Clinical and Translational Science Institute at the University of Kansas$112,315
UL1 · FY2023 · TR
Frontiers Clinical and Translational Science Institute at the University of Kansas$3,704,471
UL1 · FY2022 · TR
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$687,882
P50 · FY2020 · HD · contact PI
GOLDILOKs: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$483,485
P50 · FY2020 · HD · contact PI
Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology$102,787
T32 · FY2020 · HD
GOLDILOKs: Project 2: Translational$70,305
P50 · FY2020 · HD · contact PI
2020 Drug Metabolism Gordon Research Conference and Seminar$10,000
R13 · FY2020 · TR · contact PI
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$683,991
P50 · FY2019 · HD · contact PI
GOLDILOKs: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$394,434
P50 · FY2019 · HD · contact PI
Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology$159,236
T32 · FY2019 · HD
GOLDILOKs: Project 2: Translational$53,916
P50 · FY2019 · HD · contact PI
2019 Drug Metabolism Gordon Research Conference "Guiding Drug Development Using Translational ADME Science"$28,000
R13 · FY2019 · TR · contact PI
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$688,126
U54 · FY2018 · HD · contact PI
GOLDILOKs: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$407,413
U54 · FY2018 · HD · contact PI
Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology$222,406
T32 · FY2018 · HD
GOLDILOKs: Project 2: Translational$81,675
U54 · FY2018 · HD · contact PI
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$687,283
U54 · FY2017 · HD · contact PI
GOLDILOKs: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$666,223
U54 · FY2017 · HD · contact PI
GOLDILOKs: Project 2: Translational$164,106
U54 · FY2017 · HD · contact PI
Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology$129,270
T32 · FY2017 · HD
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$726,067
U54 · FY2016 · HD · contact PI
GOLDILOKs: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids$461,127
U54 · FY2016 · HD · contact PI
Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology$108,186
T32 · FY2016 · HD · contact PI
GOLDILOKs: Project 2: Translational$54,647
U54 · FY2016 · HD · contact PI
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics$561,688
R01 · FY2014 · HD · contact PI
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics$519,731
R01 · FY2013 · HD · contact PI
Pediatric Pharmacogenomics and Personalized Medicine$6,000
R13 · FY2013 · HD · contact PI
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics$541,978
R01 · FY2012 · HD · contact PI
Pediatric Pharmacogenomics and Personalized Medicine$6,000
R13 · FY2012 · HD · contact PI
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics$576,013
R01 · FY2011 · HD · contact PI
Pediatric Pharmacogenomics and Personalized Medicine$18,000
R13 · FY2011 · HD · contact PI
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics$539,830
R01 · FY2010 · HD · contact PI
Pediatric Pharmacogenomics and Personalized Medicine$18,000
R13 · FY2010 · HD · contact PI
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs$285,877
U01 · FY2007 · HD · contact PI
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs$294,415
U01 · FY2006 · HD · contact PI
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs$301,500
U01 · FY2005 · HD
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs$301,500
U01 · FY2004 · HD
PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME$362,663
R01 · FY2003 · GM
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs$301,500
U01 · FY2003 · HD
PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME$352,932
R01 · FY2002 · GM
PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME$356,524
R01 · FY2001 · GM
PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME$288,207
R01 · FY2000 · GM